Biofrontera AG Financials

Biofrontera Stock Summary

Biofrontera competes with NetSol Technologies, Cadence Design, CDW Corp, JD Sports, and Q2 Holdings. Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany. Biofrontera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.

Biofrontera Key Financial Ratios

Generally speaking, Biofrontera's financial ratios allow both analysts and investors to convert raw data from Biofrontera's financial statements into concise, actionable information that can be used to evaluate the performance of Biofrontera over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Biofrontera AG reports annually and quarterly.

Biofrontera Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biofrontera's current stock value. Our valuation model uses many indicators to compare Biofrontera value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biofrontera competition to find correlations between indicators driving Biofrontera's intrinsic value. More Info.Biofrontera AG is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biofrontera by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biofrontera's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biofrontera's earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

If you are still planning to invest in Biofrontera AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biofrontera's history and understand the potential risks before investing.